Evogene Ltd. (NASDAQ:EVGN) Short Interest Update

Evogene Ltd. (NASDAQ:EVGN) was the target of a large drop in short interest during the month of August. As of August 31st, there was short interest totaling 53,001 shares, a drop of 77.2% from the August 15th total of 232,078 shares. Based on an average daily volume of 219,870 shares, the short-interest ratio is currently 0.2 days. Currently, 0.7% of the shares of the company are short sold.

Insider Buying and Selling

In other Evogene news, Director Leon Recanati purchased 460,000 shares of Evogene stock in a transaction that occurred on Tuesday, August 11th. The stock was acquired at an average price of $0.64 per share, for a total transaction of $294,400.00. Following the completion of the acquisition, the director owned 1,343,886 shares of the company’s stock, valued at approximately $860,087.04. This trade represents a 52.04% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 7.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Jane Street Group LLC grew its position in Evogene by 58.0% during the first quarter. Jane Street Group LLC now owns 33,732 shares of the biotechnology company’s stock worth $42,000 after buying an additional 12,387 shares in the last quarter. XTX Topco Ltd acquired a new position in Evogene in the 4th quarter valued at $25,000. Finally, Citadel Advisors LLC lifted its position in shares of Evogene by 169.4% during the 3rd quarter. Citadel Advisors LLC now owns 57,575 shares of the biotechnology company’s stock valued at $66,000 after acquiring an additional 36,206 shares during the period. Institutional investors and hedge funds own 10.40% of the company’s stock.

Evogene Stock Performance

Shares of EVGN stock traded down $0.00 on Friday, hitting $0.48. The company’s stock had a trading volume of 2,453,974 shares, compared to its average volume of 164,677. The stock’s 50 day moving average is $0.55 and its 200-day moving average is $0.66. Evogene has a fifty-two week low of $0.37 and a fifty-two week high of $1.50. The company has a market capitalization of $4.19 million, a PE ratio of -0.53 and a beta of 1.41.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Evogene in a research note on Wednesday, July 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Evogene presently has a consensus rating of “Sell”.

About Evogene

Evogene Ltd. is a biotechnology company specializing in the use of computational and predictive biology technologies to design and develop novel products for agriculture and human health. Founded in 2002 and headquartered in Rehovot, Israel, the company has built a proprietary computational platform that integrates genomics, machine learning and data analytics to identify gene targets and biological traits. Evogene’s platform serves as the backbone for its research and development efforts, enabling the discovery of enhanced crop traits, microbial solutions and microbiome-based diagnostics and therapeutics.

In the agricultural sector, Evogene applies its platform to improve crop performance across a range of parameters, including yield enhancement, stress tolerance and resistance to pests and pathogens.